{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:16:37Z","timestamp":1791141397446,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of Chongqing","doi-asserted-by":"crossref","award":["(CSTB)2023NSCQ-BHX0127"],"award-info":[{"award-number":["(CSTB)2023NSCQ-BHX0127"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To investigate the clinical value of contrast-enhanced computed tomography (CECT) radiomics for predicting the response of primary lesions to neoadjuvant chemotherapy in hepatoblastoma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Clinical and CECT imaging data were retrospectively collected from 116 children with hepatoblastoma who received neoadjuvant chemotherapy. Tumor response was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST). Subsequently, they were randomly stratified into a training cohort and a test cohort in a 7:3 ratio. The clinical model was constructed using univariate and multivariate logistic regression, while the radiomics model was developed based on selected radiomics features employing the support vector machine algorithm. The combined clinical\u2013radiomics model incorporated both clinical and radiomics features.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The area under the curve (AUC) for the clinical, radiomics, and combined models was 0.704 (95% CI: 0.563\u20130.845), 0.830 (95% CI: 0.704\u20130.959), and 0.874 (95% CI: 0.768\u20130.981) in the training cohort, respectively. In the validation cohort, the combined model achieved the highest mean AUC of 0.830 (95% CI 0.616\u20130.999), with a sensitivity, specificity, accuracy, precision, and f1 score of 72.0%, 81.1%, 78.5%, 57.2%, and 63.5%, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>CECT radiomics has the potential to predict primary lesion response to neoadjuvant chemotherapy in hepatoblastoma.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-024-05746-x","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T12:52:08Z","timestamp":1714567928000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Predicting response of hepatoblastoma primary lesions to neoadjuvant chemotherapy through contrast-enhanced computed tomography radiomics"],"prefix":"10.1007","volume":"150","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2299-2337","authenticated-orcid":false,"given":"Yanlin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2497-0872","authenticated-orcid":false,"given":"Haoru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6640-5287","authenticated-orcid":false,"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"issue":"1","key":"5746_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00247-023-05793-5","volume":"54","author":"Y Chen","year":"2024","unstructured":"Chen Y, Froelich MF, Tharmaseelan H et al (2024) Computed tomography imaging phenotypes of hepatoblastoma identified from radiomics signatures are associated with the efficacy of neoadjuvant chemotherapy. Pediatr Radiol 54(1):58\u201367. https:\/\/doi.org\/10.1007\/s00247-023-05793-5","journal-title":"Pediatr Radiol"},{"issue":"Suppl 1","key":"5746_CR2","doi-asserted-by":"publisher","first-page":"S145","DOI":"10.1016\/j.acra.2020.10.020","volume":"29","author":"S Choudhery","year":"2022","unstructured":"Choudhery S, Gomez-Cardona D, Favazza CP et al (2022) MRI Radiomics for assessment of molecular subtype, pathological complete response, and residual cancer burden in breast cancer patients treated with neoadjuvant chemotherapy. Acad Radiol 29(Suppl 1):S145\u2013S154. https:\/\/doi.org\/10.1016\/j.acra.2020.10.020","journal-title":"Acad Radiol"},{"issue":"4","key":"5746_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jhep.2023.05.031","volume":"79","author":"A Claver\u00eda-Cabello","year":"2023","unstructured":"Claver\u00eda-Cabello A, Herranz JM, Latasa MU et al (2023) Identification and experimental validation of druggable epigenetic targets in hepatoblastoma. J Hepatol 79(4):989\u20131005","journal-title":"J Hepatol"},{"issue":"2","key":"5746_CR4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1148\/radiol.2015151169","volume":"278","author":"RJ Gillies","year":"2016","unstructured":"Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: images are more than pictures, they are data. Radiology 278(2):563\u2013577. https:\/\/doi.org\/10.1148\/radiol.2015151169","journal-title":"Radiology"},{"issue":"3","key":"5746_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118261","volume":"10","author":"O Grove","year":"2015","unstructured":"Grove O, Berglund AE, Schabath MB et al (2015) Quantitative computed tomographic descriptors associate tumor shape complexity and intratumor heterogeneity with prognosis in lung adenocarcinoma. PLoS ONE 10(3):e0118261","journal-title":"PLoS ONE"},{"issue":"6","key":"5746_CR6","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s11307-023-01870-1","volume":"25","author":"J Gu","year":"2023","unstructured":"Gu J, Bao S, Akemuhan R, Jia Z, Zhang Y, Huang C (2023) Radiomics based on contrast-enhanced CT for recognizing c-Met-positive hepatocellular carcinoma: a noninvasive approach to predict the outcome of sorafenib resistance. Mol Imaging Biol 25(6):1073\u20131083. https:\/\/doi.org\/10.1007\/s11307-023-01870-1","journal-title":"Mol Imaging Biol"},{"issue":"8","key":"5746_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28350","volume":"67","author":"B Haeberle","year":"2020","unstructured":"Haeberle B, Rangaswami A, Krailo M et al (2020) The importance of age as prognostic factor for the outcome of patients with hepatoblastoma: analysis from the children\u2019s hepatic tumors International Collaboration (CHIC) database. Pediatr Blood Cancer 67(8):e28350. https:\/\/doi.org\/10.1002\/pbc.28350","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"5746_CR8","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/j.jpedsurg.2016.09.038","volume":"51","author":"E Hiyama","year":"2016","unstructured":"Hiyama E, Hishiki T, Watanabe K et al (2016) Resectability and tumor response after preoperative chemotherapy in hepatoblastoma treated by the Japanese Study Group for Pediatric Liver Tumor (JPLT)-2 protocol. J Pediatr Surg 51(12):2053\u20132057","journal-title":"J Pediatr Surg"},{"issue":"22","key":"5746_CR9","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1200\/JCO.19.01067","volume":"38","author":"E Hiyama","year":"2020","unstructured":"Hiyama E, Hishiki T, Watanabe K et al (2020) Outcome and late complications of hepatoblastomas treated using the Japanese Study Group for pediatric liver tumor 2 protocol. J Clin Oncol 38(22):2488\u20132498. https:\/\/doi.org\/10.1200\/JCO.19.01067","journal-title":"J Clin Oncol"},{"key":"5746_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.644994","volume":"11","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Sun J, Xia Y et al (2021) Preoperative assessment for event-free survival with hepatoblastoma in pediatric patients by developing a CT-based radiomics model. Front Oncol 11:644994. https:\/\/doi.org\/10.3389\/fonc.2021.644994","journal-title":"Front Oncol"},{"issue":"12","key":"5746_CR11","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1002\/cncr.30591","volume":"123","author":"HM Katzenstein","year":"2017","unstructured":"Katzenstein HM, Furman WL, Malogolowkin MH et al (2017) Upfront window vincristine\/irinotecan treatment of high-risk hepatoblastoma: a report from the Children\u2019s Oncology Group AHEP0731 study committee. Cancer 123(12):2360\u20132367. https:\/\/doi.org\/10.1002\/cncr.30591","journal-title":"Cancer"},{"issue":"5","key":"5746_CR12","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S1470-2045(18)30895-7","volume":"20","author":"HM Katzenstein","year":"2019","unstructured":"Katzenstein HM, Langham MR, Malogolowkin MH et al (2019) Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731). A Children\u2019s Oncology Group, multicentre, phase 3 trial. Lancet Oncol 20(5):719\u2013727. https:\/\/doi.org\/10.1016\/S1470-2045(18)30895-7","journal-title":"Lancet Oncol"},{"issue":"24","key":"5746_CR13","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1200\/JCO.2010.29.3837","volume":"29","author":"MH Malogolowkin","year":"2011","unstructured":"Malogolowkin MH, Katzenstein HM, Meyers RL et al (2011) Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children\u2019s Oncology Group. J Clin Oncol 29(24):3301\u20133306. https:\/\/doi.org\/10.1200\/JCO.2010.29.3837","journal-title":"J Clin Oncol"},{"issue":"3","key":"5746_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3390\/cancers11030407","volume":"11","author":"JJG Marin","year":"2019","unstructured":"Marin JJG, Cives-Losada C, Asensio M, Lozano E, Briz O, Macias RIR (2019) Mechanisms of anticancer drug resistance in hepatoblastoma. Cancers 11(3):407. https:\/\/doi.org\/10.3390\/cancers11030407","journal-title":"Cancers"},{"key":"5746_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nrc3261","volume":"12","author":"A Marusyk","year":"2012","unstructured":"Marusyk A, Almendro V, Polyak K (2012) Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 12:323\u2013334","journal-title":"Nat Rev Cancer"},{"key":"5746_CR16","doi-asserted-by":"publisher","first-page":"4090","DOI":"10.1002\/cncr.26715","volume":"118","author":"RL Meyers","year":"2012","unstructured":"Meyers RL, Tiao GM, Dunn SP, McGahren ED III, Langham MR Jr (2012) Surgical management of children with locally advanced hepatoblastoma. Cancer 118:4090\u20134091","journal-title":"Cancer"},{"issue":"1","key":"5746_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S1470-2045(16)30598-8","volume":"18","author":"RL Meyers","year":"2017","unstructured":"Meyers RL, Maibach R, Hiyama E et al (2017) Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children\u2019s Hepatic tumors International Collaboration. Lancet Oncol 18(1):122\u2013131. https:\/\/doi.org\/10.1016\/S1470-2045(16)30598-8","journal-title":"Lancet Oncol"},{"issue":"3","key":"5746_CR18","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ejca.2003.06.003","volume":"40","author":"G Perilongo","year":"2004","unstructured":"Perilongo G, Shafford E, Maibach R et al (2004) Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the International Society of Paediatric Oncology\u2014SIOPEL 2. Eur J Cancer 40(3):411\u2013421. https:\/\/doi.org\/10.1016\/j.ejca.2003.06.003","journal-title":"Eur J Cancer"},{"issue":"22","key":"5746_CR19","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.1200\/JCO.2000.18.22.3819","volume":"18","author":"J Pritchard","year":"2000","unstructured":"Pritchard J, Brown J, Shafford E, Perilongo G, Brock P, Dicks-Mireaux C, Keeling J, Phillips A, Vos A, Plaschkes J (2000) Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach\u2013results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol 18(22):3819\u20133828","journal-title":"J Clin Oncol"},{"issue":"6","key":"5746_CR20","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.jhep.2011.10.028","volume":"56","author":"AL Rougemont","year":"2012","unstructured":"Rougemont AL, McLin VA, Toso C, Wildhaber BE (2012) Adult hepatoblastoma: learning from children. J Hepatol 56(6):1392\u20131403. https:\/\/doi.org\/10.1016\/j.jhep.2011.10.028","journal-title":"J Hepatol"},{"issue":"3","key":"5746_CR21","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3390\/diagnostics13030486","volume":"13","author":"I Sharaby","year":"2023","unstructured":"Sharaby I, Alksas A, Nashat A et al (2023) Prediction of Wilms\u2019 tumor susceptibility to preoperative chemotherapy using a novel computer-aided prediction system. Diagnostics 13(3):486. https:\/\/doi.org\/10.3390\/diagnostics13030486","journal-title":"Diagnostics"},{"issue":"1","key":"5746_CR22","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.1038\/s41467-022-32473-z","volume":"13","author":"H Song","year":"2022","unstructured":"Song H, Bucher S, Rosenberg K et al (2022) Single-cell analysis of hepatoblastoma identifies tumor signatures that predict chemotherapy susceptibility using patient-specific tumor spheroids. Nat Commun 13(1):4878","journal-title":"Nat Commun"},{"key":"5746_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guide-lines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"5746_CR24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/bjs.9681","volume":"102","author":"R Venkatramani","year":"2015","unstructured":"Venkatramani R, Stein JE, Sapra A et al (2015) Effect of neoadjuvant chemotherapy on resectability of stage III and IV hepatoblastoma. Br J Surg 102(1):108\u2013113. https:\/\/doi.org\/10.1002\/bjs.9681","journal-title":"Br J Surg"},{"issue":"8","key":"5746_CR25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.21143","volume":"4","author":"W Wang","year":"2021","unstructured":"Wang W, Peng Y, Feng X et al (2021) Development and validation of a computed tomography-based radiomics signature to predict response to neoadjuvant chemotherapy for locally advanced gastric cancer. JAMA Netw Open 4(8):e2121143. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.21143","journal-title":"JAMA Netw Open"},{"issue":"13","key":"5746_CR26","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1007\/s00247-023-05792-6","volume":"53","author":"H Wang","year":"2023","unstructured":"Wang H, Chen X, He L (2023a) A narrative review of radiomics and deep learning advances in neuroblastoma: updates and challenges. Pediatr Radiol 53(13):2742\u20132755. https:\/\/doi.org\/10.1007\/s00247-023-05792-6","journal-title":"Pediatr Radiol"},{"issue":"3","key":"5746_CR27","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s00261-022-03774-0","volume":"48","author":"H Wang","year":"2023","unstructured":"Wang H, Qin J, Chen X et al (2023b) Contrast-enhanced computed tomography radiomics in predicting primary site response to neoadjuvant chemotherapy in high-risk neuroblastoma. Abdom Radiol 48(3):976\u2013986. https:\/\/doi.org\/10.1007\/s00261-022-03774-0","journal-title":"Abdom Radiol"},{"issue":"2","key":"5746_CR28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3760\/cma.j.cn112140-20210601-00472","volume":"60","author":"LL Wei","year":"2022","unstructured":"Wei LL, Ran Y, Li B et al (2022) Clinical characteristics and prognosis of 83 children with newly treated hepatoblastoma. Zhonghua Er Ke Za Zhi 60(2):108\u2013113. https:\/\/doi.org\/10.3760\/cma.j.cn112140-20210601-00472","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"9","key":"5746_CR29","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s11912-022-01230-2","volume":"24","author":"PV Wu","year":"2022","unstructured":"Wu PV, Rangaswami A (2022) Current Approaches in Hepatoblastoma-New Biological Insights to Inform Therapy. Curr Oncol Rep 24(9):1209\u20131218. https:\/\/doi.org\/10.1007\/s11912-022-01230-2","journal-title":"Curr Oncol Rep"},{"issue":"11","key":"5746_CR30","doi-asserted-by":"publisher","first-page":"8765","DOI":"10.1007\/s00330-021-07962-2","volume":"31","author":"Q Xu","year":"2021","unstructured":"Xu Q, Sun Z, Li X et al (2021) Advanced gastric cancer: CT radiomics prediction and early detection of downstaging with neoadjuvant chemotherapy. Eur Radiol 31(11):8765\u20138774. https:\/\/doi.org\/10.1007\/s00330-021-07962-2","journal-title":"Eur Radiol"},{"issue":"9","key":"5746_CR31","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1470-2045(13)70272-9","volume":"14","author":"J Zsiros","year":"2013","unstructured":"Zsiros J, Brugieres L, Brock P et al (2013) Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol 14(9):834\u2013842. https:\/\/doi.org\/10.1016\/S1470-2045(13)70272-9","journal-title":"Lancet Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05746-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05746-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05746-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T03:20:50Z","timestamp":1717989650000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05746-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["5746"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05746-x","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,30]]},"assertion":[{"value":"26 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Our retrospective cohort study was authorized by the Ethics Committee of the Children\u2019s Hospital of Chongqing Medical University (File No. 2023-472), which consented to waive informed consent because the data used in this study have no personally identifiable information of patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"223"}}